Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Int J Hyperthermia. 2019;36(1):817–826. doi: 10.1080/02656736.2019.1642521

Figure 5. Plasma pharmacokinetics.

Figure 5.

a) Plasma concentration of Dox was measured after injection of TSL-Dox, and after completion of hyperthermia in each of the groups (15, 30, 60 min). Plasma half-life was 56.0 ± 15.9 min. b) Plasma concentration of Dox was measured at 6 min and 75 min after injection with animals on either 34 °C or 37 °C thermal support inside the imaging system. At 37 °C thermal support, core temperature was elevated above 39 °C, resulting in accelerated systemic leakage from TSL and a diminished plasma half-life.